H.R. 6958 — Introduced in House

I 115th CONGRESS 2d Session H. R. 6958 IN THE HOUSE OF REPRESENTATIVES September 27, 2018Mr. Francis Rooney of Florida (for himself and Mr. Welch) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development. 1. Short title This Act may be cited as the Drug Price Transparency Act. 2. Study and report on feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on average prices for such drugs in OECD member states From amounts otherwise made available to the Secretary of Health and Human Services, the Secretary shall use not to exceed $100,000 of such amounts to, not later than 90 days after the date of the enactment of this Act, conduct a study, and submit to Congress a report, on the feasibility of— (1) basing reimbursement rates under part B of the Medicare program under title XVIII of the Social Security Act for prescription drugs for which coverage is provided under part B of the Medicare program on the average price of such drugs in the member-states of the Organization for Economic Cooperation and Development; and (2) basing payment rates under prescription drug plans under part D of such title (and under MA–PD plans under part C of such title) for covered part D drugs (as defined in section 1860D–2(e) of such Act (42 U.S.C. 1395w–102(e))) on the average price of such drugs in such member-states.